Imagenebio, INC. (IMA) — 10-Q Filings

All 10-Q filings from Imagenebio, INC.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

ImageneBio's Losses Mount Amid Soaring R&D, Cash Position Strengthens Post-PIPE — Nov 12, 2025 Risk: high
ImageneBio, Inc. reported a significant increase in net loss for the three months ended September 30, 2025, reaching $24.779 million, up from $3.183 million in
Ikena Narrows Losses Amid Inmagene Merger Ahead of Immunology Pivot — Jul 24, 2025 Risk: high
Ikena Oncology, Inc. reported a net loss of $13.5 million for the three months ended June 30, 2025, a significant improvement from the $23.2 million net loss in
Ikena Oncology Files Q1 2025 10-Q, Details Merger & Loan — May 8, 2025 Risk: medium
Ikena Oncology, Inc. filed a 10-Q for the period ending March 31, 2025. The company reported on its financial condition and business operations, including detai
Ikena Oncology Q3 2024 Update — Nov 7, 2024 Risk: medium
Ikena Oncology, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the third quarter of 20
Ikena Oncology Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
Ikena Oncology, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial condition and results of operations, including de
Ikena Oncology, Inc. Files 10-Q for Period Ending March 31, 2024 — May 13, 2024 Risk: medium
Ikena Oncology, Inc. (IMA) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Ikena Oncology reported financial results for the quarter ended March 3

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX